1. Most Discussed
  2. Gainers & Losers

Prima BioMed announces second milestone payment for IMP701 program

Bookmark and Share
  1. July 17 (Reuters) - Prima BioMed

    • it will receive a second undisclosed significant clinical milestone payment from Novartis
    • payment based on collaboration and licensing agreement between companies, relating to Prima's imp701 lag-3 antibody
    Discuss this via PRR

Before making any financial decisions based on what you read, always consult an advisor or expert.

The aim of HotCopper News is to report and comment on news in the financial and investment markets. HotCopper provides no advice on dealing in securities and is not a financial advisor. Professional advice should be sought before making any investment decisions.

Contact editor: [email protected]

To read reuters' full disclaimer click here

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.